Emergent BioSolutions to Acquire Trubion Pharmaceuticals
Emergent BioSolutions Inc. (NYSE: EBS) announced today it has entered into a definitive agreement to acquire Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) for upfront consideration of $96.8 million of...
Emergent BioSolutions and Temasek Life Sciences Ventures Establish Joint Venture to Develop Broad Spectrum Pandemic Flu Vaccine and Therapeutic
Temasek Life Science Ventures Pte Ltd (TLV) and Emergent BioSolutions Inc. (NYSE:EBS) today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and...
Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2010
Total revenues for the second quarter and first six months of 2010 were $62.1 million and $108.9 million, respectively. Net income for the second quarter and first six months of 2010 was $9.8...
Emergent Revises Upward 2010 Financial Forecast
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of $40 to...
Maryland Governor Martin O’Malley Leads Ribbon Cutting Ceremony at Emergent’s Baltimore Manufacturing Facility
Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon cutting ceremony, led by Governor Martin O'Malley and Fuad El-Hibri, Emergent's chairman and chief executive officer, to mark the formal...
Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA)...
Emergent BioSolutions to Release Second Quarter 2010 Financial Results and Conduct a Conference Call on August 5, 2010
Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for second quarter 2010 on Thursday August 5, 2010, after market...
Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians
Emergent BioSolutions Inc. (NYSE:EBS) is hosting "Bioterrorism Prevention, Preparedness and Response," a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary...
Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments
ROCKVILLE, Md., Jun 24, 2010 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed separate international sales and deliveries of BioThrax(R) (Anthrax Vaccine...
Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors
ROCKVILLE, Md., Jun 04, 2010 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company's Board of Directors appointed Marvin White as a Class II Director for a one-year...
Emergent BioSolutions to Participate in June 2010 Investor Conferences
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body's immune system to...
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 20, 2010 at 10:00 am Eastern; Webcast Will Be Available
ROCKVILLE, Md., May 19, 2010 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will hold its Annual Meeting of Stockholders on Thursday, May 20, 2010 beginning at 10:00...